newsfilter
← Latest News
GlobeNewswire·

Immatics Announces Third Quarter 2023 Financial Results and Business Update

ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including responses ongoing at